 InflaRx to present initial data at the SVB Leerink Global Healthcare Conference today at 9:00 am EST 3:00 pm CET. JENA, Germany, Feb. 26, 2020 GLOBE NEWSWIRE -- InflaRx N.V. IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces positive initial data from the first 5 patients in the Phase IIa open label study with IFX-1 in patients suffering from Pyoderma Gangraenosum PG. PG is a rare and debilitating neutrophil-driven, autoinflammatory skin disease, characterized by an acute, destructive ulcerating process of the skin, primarily occurring on the legs but also other regions of the body. 